Faran Shimi Pharmaceutical Company

What Faran Shimi Pharmaceutical Company does

Faran Shimi Pharmaceutical Company (شرکت داروسازی فاران شیمی) is an Iran-based pharmaceutical manufacturer founded in 2002 as a productive cooperative in the Touserkans Industrial Town and currently operating as a subsidiary of the Golrang Pharmaceutical Investment Group following its 2010 incorporation into the holding. The company is organized into two core segments: Active Pharmaceutical Ingredients (APIs), with both Low Volume High Value (LVHV) and Mass production lines including proprietary opium extraction and processing operations; and Finished Pharmaceutical Products (F.P), spanning tablets, capsules, syrups, and hemodialysis solution with an annual tablet capacity of 150 million units.

Its product portfolio addresses pain management (Faroxy/Oxycodone), addiction treatment (buprenorphine sublingual tablets and APIs), neurology (Fampiron/Fampridine for multiple sclerosis, Miglusca/Miglustat for Gaucher and Niemann-Pick Type C disease), ADHD (Attvanse/Lisdexamfetamine), plus dietary supplements under the Octaheal and Duralife sub-brands and disinfectant products (Colonianti hand sanitizer). Manufacturing takes place at a 17,000-square-meter facility with over 350 direct personnel and capacity to reach 500 with new production lines, with GMP certification from the Iranian Ministry of Health covering opium processing and pharmaceutical operations.

The business model is anchored in selling prescription and OTC pharmaceuticals through Iranian pharmacy networks, hospital procurement channels, and B2B API supply to other domestic manufacturers (notably as the exclusive supplier of buprenorphine hydrochloride API to all other Iranian companies licensed for buprenorphine production). Pricing is administered under Iranian pharmaceutical regulations and insurance reimbursement systems. The company also operates Faran Plus, a patient support department providing drug information and counseling, and runs content marketing through a Persian-language health magazine. Customer-facing outreach extends to Instagram, Telegram, and participation in scientific congresses such as the 1403 Addiction Science Congress as Platinum Sponsor. As of fiscal 1402 (March 2023 to March 2024), the company reported 1,000 billion Toman (one trillion Toman) in annual sales.

Name

Faran Shimi Pharmaceutical Company

Legal name

Faran Shimi Pharmaceutical Company (شرکت داروسازی فاران شیمی)

Website

https://faranshimi.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

251–500 employees

Short description

Faran Shimi Pharmaceutical Company is an Iran-based pharmaceutical manufacturer, subsidiary of Golrang Pharmaceutical Investment Group, producing narcotic APIs, finished dosage drugs for pain, addiction, neurology, and chronic disease, plus dietary supplements and disinfectants for domestic pharmacy and hospital distribution.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Soap and Cleaning Compound Manufacturing (32561), Chemical Manufacturing (325)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Hand Sanitizers & Antibacterial Personal Care (CRADANAI), Gastrointestinal & Digestive Health (HLAIADAD), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB), Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• Narcotic medications
• Active pharmaceutical ingredients
• Addiction treatment drugs
• Dietary supplements

Headquarters

HQ city

Tuyserkan

HQ country

Iran

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Finished Pharmaceutical Products (F.P): Production and sale of finished dosage form drugs including tablets, capsules, and syrups across therapeutic categories
2. Active Pharmaceutical Ingredients (APIs): Production and sale of narcotic drug APIs including buprenorphine hydrochloride, serving domestic and export markets
3. Disinfectant and Consumer Products: Production of sanitizing and disinfectant products including Colonianti hand sanitizer

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Faran Shimi Pharmaceutical Company is an Iranian pharmaceutical manufacturer that produces and sells active pharmaceutical ingredients (APIs), including narcotic and opioid substances such as buprenorphine hydrochloride, and finished dosage form drugs (tablets, capsules, syrups) across therapeutic categories including pain management, addiction treatment, multiple sclerosis, Gaucher disease, ADHD, diabetes, cardiovascular, renal, gastrointestinal, and respiratory conditions. The company also produces a dietary supplement line and disinfectant consumer products, with all narcotic-related manufacturing carried out under GMP certification from the Iran Ministry of Health.

Product overview

Faran Shimi Pharmaceutical Company is an Iranian pharmaceutical manufacturer organized under the Golrang Industrial Group. The company operates two main segments: Active Pharmaceutical Ingredients (APIs) including narcotic/opioid substances, and Finished Pharmaceutical Products (F.P). API production includes both Low Volume High Value (LVHV) and Mass volume product lines. The finished products portfolio spans multiple therapeutic categories including pain management (Faroxy/Oxycodone, Attvanse/Lisdexamfetamine), neurological disorders (Fampiron/Fampridine for MS, Miglusca/Miglustat for Gaucher/Niemann-Pick disease), and addiction treatment (Buprenorphine products). The company also produces a diverse supplement line under the Octaheal and Duralife sub-brands covering kidney support (Duralife Kidney), diabetes support (Duralife Diabetes), women's health (Duralife Saffron PMS), general wellness (Octaheal B12, Magnesium Plus B6, Colostrum, Biocell Collagen), and digestive health (Octa-Herbal Slippery Elm), plus disinfectant products (Colonianti hand sanitizer).

Differentiator

Problem solved

Functional benefit

Brands

• Faran Plus (فاران پلاس): Patient support and healthcare advisory department of Faran Shimi, providing drug information, patient counseling, and 24-hour support services for patients using the company's products.
• Cologni Anti
• Octaheal (اکتاهیل)
• DuraLife (دورالایف)
• Faroxy (فاروکسی)
• Fampiron (فمپیرون)

Products and services

• Fampiron (فمپیرون) Fampridine 10 mg sustained-release tablet for improving walking ability in adult patients with multiple sclerosis (MS). Distributed through Iranian pharmacies under physician prescription.
• Faroxy (فاروکسی) Oxycodone immediate-release tablets in 5, 15, and 30 mg doses plus extended-release Faroxy-ER in 10, 20, and 40 mg doses for moderate to severe pain management. Produced by Faran Shimi for prescription use.
• Attvanse (اَتونس) Lisdexamfetamine dimesylate capsules in 30, 50, and 70 mg strengths for the treatment of ADHD and moderate to severe binge eating disorder in adults. Produced by Faran Shimi.
• Miglusca (میگلوسکا) Miglustat 100 mg capsules, a glucosylceramide synthase inhibitor used for treating Type 1 Gaucher disease and neurological symptoms of Niemann-Pick Disease Type C. Produced by Faran Shimi.
• Octaheal B12 (اکتاهیل ب12) Cyanocobalamin (Vitamin B12) 1000 microgram capsules designed to meet daily Vitamin B12 requirements and support red blood cell production and nervous system function.
• Octaheal Biocell Collagen (اکتاهیل بایوسل کلاژن) Dietary supplement containing hyaluronic acid, chondroitin sulfate, and hydrolyzed collagen extracted from chicken sternum cartilage, supporting joint health, cartilage function, skin elasticity, and anti-aging.
• Octaheal Colostrum (اکتاهیل کلستروم) Colostrum dietary supplement designed to strengthen the immune system and improve overall health. Produced by Faran Shimi.
• Octaheal Magnesium Plus B6 (اکتاهیل منیزیم پلاس ب6) Magnesium plus Vitamin B6 dietary supplement. Produced by Faran Shimi.
• Octa-Herbal Slippery Elm (اکتاهربال اسلیپری اِلم) Slippery elm (Ulmus rubra) inner bark supplement for digestive health, soothing gastrointestinal inflammation, stomach ulcers, colitis, diarrhea, and constipation. Produced by Faran Shimi.
• Duralife Kidney (دورالایف کلیه) Specialized nutritional supplement for chronic kidney disease (CKD) patients, containing vitamins B1, B2, B3, B5, B6, B7, B9, B12, C, E, plus iron, zinc, selenium, and copper; one tablet daily with main meal.
• Duralife Diabetes (دورالایف دیابت) Multivitamin-mineral supplement formulated for diabetic patients to support glucose metabolism, blood sugar control, and prevention of diabetes complications.
• Duralife Saffron, Magnesium and B6 (دورالایف زعفران، منیزیم و ب6) Supplement containing saffron extract 30 mg, magnesium 200 mg, and Vitamin B6 25 mg, formulated to improve premenstrual syndrome (PMS) symptoms with anti-depressive effects; sugar-free, gluten-free, lactose-free.
• Colonianti Hand Sanitizer (کولونیاآنتی) 70% alcohol hand sanitizer available in strawberry, lavender, orange, and snow flower fragrances, providing antibacterial and antiviral protection.
• Active Pharmaceutical Ingredients (APIs) Active Pharmaceutical Ingredients including buprenorphine hydrochloride and other narcotic/opioid substances for addiction treatment, with LVHV (Low Volume High Value) and Mass production lines; supplied to other licensed Iranian pharmaceutical manufacturers.
• Hemodialysis Solution (محلول همودیالیز) Hemodialysis solution production line as part of the finished pharmaceutical products segment for use in dialysis treatment.

Quantifiable outcome

• 30-40% of MS patients show significant improvement in walking speed and quality with Fampridine treatment
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Tehran Pharma (TPICO): Holding company for major Iranian pharmaceutical manufacturers including Darou Pakhsh and several other branded generic producers. Direct peer given overlapping API manufacturing, finished-dose production, and domestic pharmacy distribution in Iran.
• Rhodes Pharmaceuticals: US-based generic manufacturer specializing in controlled substances including oxycodone and buprenorphine. Direct peer given shared focus on opioid API and finished-dose production for pain and addiction treatment.
• Barakat Pharmaceutical Group: Iranian government-affiliated pharma group producing APIs, finished dosage forms, and biotech products. Closely comparable as an Iranian API-to-finished-product manufacturer competing in similar therapeutic categories including addiction treatment and pain management.
• Darou Pakhsh Pharmaceutical Manufacturing Co. Iran's largest state-affiliated pharmaceutical manufacturer and part of TPICO. Directly comparable as a broad-portfolio Iranian pharma that manufactures APIs and finished dosage forms for both narcotics-adjacent and chronic-disease therapeutic areas domestically.
• Sobhan Oncology: Iranian specialty pharma focused on oncology and chronic-disease products. Direct peer given shared domestic Iranian manufacturing footprint, hospital and pharmacy distribution, and overlap in chronic-disease therapeutic categories.
• Darou Bartar: Iranian pharmaceutical manufacturer producing finished dosage forms across chronic and specialty therapeutic areas. Comparable as a domestic Iranian peer competing for the same pharmacy and hospital channel.
• Shafa Daroo: Iranian producer of finished dosage forms including pain and addiction-treatment products. Direct peer as a domestic Iranian competitor in opioid and chronic-disease finished-dose manufacturing.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Global specialty pharmaceutical company with a substantial controlled-substances franchise (oxycodone, buprenorphine, methadone). Comparable as a much larger incumbent in the same controlled-substance API and finished-dose categories that Faran Shimi specializes in domestically.
• Purdue Pharma: US specialty pharma historically focused on opioid analgesics (OxyContin) and addiction treatment. Broader incumbent comparable given overlapping focus on oxycodone, controlled-release opioid technology, and addiction-treatment APIs that mirror Faran Shimi's Faroxy and buprenorphine lines.
• Johnson Matthey (Controlled Substances business): British specialty chemicals and APIs manufacturer with a controlled-substances platform supplying narcotic APIs. Comparable as an international incumbent in the controlled-substance API space that Faran Shimi competes in regionally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/faranshimi
• Facebookfacebook.com/faranshimi
• LinkedInlinkedin.com/company/faranshimi

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Faran Shimi Pharmaceutical Company